Article Details
Retrieved on: 2025-01-02 17:46:13
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses OS Therapies' engagement with capital markets through attendance at the J.P. Morgan Healthcare Conference and plans to raise funds by leveraging FDA incentives, linking their cancer treatment advancements, particularly with OST-HER2, with tags related to breast cancer, antineoplastic drugs, and immunology.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here